Forming Meaningful Pharma–Academia Partnerships

By George Vratsanos and Dawn Waterworth

No matter the vantage point within the pharmaceutical industry, R&D priorities are always evolving. In large pharma, investment in R&D is increasingly expensive relative to the number of new medicines brought to market. Similarly, small biotechnology companies are often facing funding challenges and must find new ways to accomplish the same lifesaving work with less capital and infrastructure. Despite this, the mission remains the same across this spectrum of life sciences companies — to bring transformational, new medicines to market that will deeply improve lives.